No Data
No Data
Qingdao Haier Biomedical Co., Ltd. (688139): The dawn of a turning point in 2024 has arrived, and the Business is fully recovering.
The operational turning point for 2024 has arrived, the business has fully recovered, maintaining a "Buy" rating. The company achieved revenue of 2.284 billion yuan in 2024 (yoy +0.13%), with a net income of 0.367 billion yuan (yoy -9.
Haier Biotech 2024 Annual Report Summary
Haier Biotech 2024 Annual Report
Qingdao Haier Biomedical Co., Ltd. (688139.SH) released its performance for the year 2024, with a net income of 0.367 billion yuan, a decrease of 9.71% compared to the previous year.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) disclosed its annual report for 2024, stating that the company's revenue during the reporting period reached 22.84...
Qingdao Haier Biomedical Co., Ltd. (688139): The dual wings of life sciences and medical innovation soar together, with platformization and globalization opening up new growth boundaries.
A leader in the domestic low-temperature storage Industry, focusing on platformization and Global exploration of growth potential. The company has been deeply engaged in the low-temperature storage Business for twenty years and has since transformed into a comprehensive solution provider in biotechnology based on Internet of Things Technology. The company has a complete product line, and the low-temperature storage Business has been fully developed.
Express News | DeepSeek-R2 will be released on March 17, and there has been no official response yet.